Peptide Therapy: Sorting the Real Evidence From the Hype

"Peptide therapy" shows up everywhere right now -- in wellness clinics, direct-to-consumer kits, and group chats where people compare vials of BPC-157 or CJC-1295 like they're comparing protein powder. The term covers an enormous range of things, from medications your insurance already covers to compounds with almost no human safety data. That range matters. Before you consider any peptide, it helps to know which bucket it actually falls into.

What a peptide actually is

A peptide is simply a short chain of amino acids, shorter than a full protein. That definition covers insulin, the GLP-1 medications like semaglutide and tirzepatide, and the growth-hormone peptides sold online without a prescription. Being "a peptide" tells you nothing about whether a compound works or is safe -- it only describes its chemical structure. The real question for any specific peptide is the same question we'd ask about any other treatment: what does the human evidence show, and who studied it.

The peptides with solid human evidence behind them

Some peptide-based medications have already gone through the normal drug approval process, with randomized trials, defined doses, and FDA oversight.

GLP-1 receptor agonists -- semaglutide and tirzepatide -- are the best-studied peptides in medicine right now. Beyond their original approval for diabetes and weight management, large cardiovascular outcome trials have found reductions in major cardiovascular events, heart failure, and kidney disease progression in people with obesity or type 2 diabetes (Jang et al., 2026).

Bremelanotide (brand name Vyleesi) is a peptide the FDA approved in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women (FDA approval letter, 2019). In the phase 3 RECONNECT trials, it produced modest but statistically significant improvements in sexual desire and reductions in related distress compared with placebo, across age, weight, and testosterone subgroups (Simon et al., 2022). It isn't a cure-all, and side effects like nausea, flushing, and transient blood pressure increases are common enough that it isn't the right fit for everyone.

Tesamorelin, a growth-hormone-releasing peptide, also carries FDA approval, but for a narrow indication: excess abdominal fat in people with HIV-associated lipodystrophy. That approval doesn't extend to general fat loss or anti-aging use.

The peptides still waiting on evidence

Most of what circulates online as "peptide therapy" hasn't cleared that bar yet.

Growth hormone secretagogues -- sermorelin, ipamorelin, CJC-1295, and ibutamoren are the names you'll see most often -- reliably raise growth hormone and IGF-1 levels in the blood. A 2026 review of peptides used in urology and sexual medicine found that despite this predictable hormonal effect, evidence that they improve physical performance, sexual function, or quality of life "remains limited" (Vasylieva et al., 2026). Moving a lab number is not the same as feeling or functioning better.

BPC-157 is probably the most talked-about research peptide right now, marketed for joint pain, gut healing, and tendon recovery. A systematic review published in 2026 searched every available human study and found exactly three, with 30 participants combined, none of them randomized or placebo-controlled (Poolton et al., 2026). The review's conclusion was blunt: the certainty of evidence is very low, and BPC-157 "should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials." The animal data for BPC-157 is much larger and more encouraging, which is part of why it has built such a following online, but healing patterns in rodents don't reliably predict what happens in people.

Melanotan II and kisspeptin fall into a similar category: biologically plausible and actively studied, but not yet supported by trials large or rigorous enough to guide routine clinical use (Vasylieva et al., 2026).

Why the unregulated peptide market carries real risk

Here's where the evidence gap turns into an actual safety problem. Many of the peptides above are sold directly to consumers as "research chemicals," not medications, which means they skip the manufacturing standards, purity testing, and dosing consistency that FDA-approved drugs require. The same review of peptides in sexual medicine flagged this directly, noting that agents like Melanotan II, ibutamoren, and CJC-1295 remain accessible through unregulated markets, "raising concerns about product quality, dosing variability, and incompletely characterized adverse effects" (Vasylieva et al., 2026).

The regulatory status of some of these compounds, including BPC-157, is also actively under review, with bulk drug substance lists and compounding rules shifting as agencies weigh new safety nominations. That instability is one more reason to be skeptical of anyone selling a peptide as settled science.

How to think about peptide therapy if you're considering it

None of this means every peptide is hype, or that functional medicine should ignore this category. It means the same rule applies here as everywhere else in medicine: start with your actual labs and symptoms, not with a trending compound. A GLP-1 medication or bremelanotide might genuinely fit your situation, with real trial data behind that decision. A less-studied peptide might still be worth an honest conversation, including what isn't known yet, rather than being sold to you as a guaranteed fix.

If a clinic can't tell you which category a peptide falls into, or treats "it's a peptide" as reassurance on its own, that's a sign to ask more questions before you start anything.

If you're trying to sort out what's actually evidence-based for your health goals, including whether a peptide-based treatment makes sense for you, a functional medicine visit starts with your labs and history, not a sales pitch. Most major plans are accepted, including Medicare.